Vimarsana
Biggest News Aggregation in the World

Page 32 - Jason Ehrlich News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jason Ehrlich. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jason Ehrlich Today - Breaking & Trending Today

Kodiak Sciences (NASDAQ:KOD) Given New $12.00 Price Target at Morgan Stanley - Vimarsana News

Kodiak Sciences (NASDAQ:KOD) Given New $12.00 Price Target at Morgan Stanley

Kodiak Sciences (NASDAQ:KOD – Get Rating) had its price target cut by Morgan Stanley from $17.00 to $12.00 in a report issued on Tuesday, MarketBeat reports. They currently have an equal weight rating on the stock. Several other analysts have also recently issued reports on KOD. JPMorgan Chase & Co. cut Kodiak Sciences from an […]

Brokerages Expect Kodiak Sciences Inc. (NASDAQ:KOD) Will Announce Earnings of -$1.47 Per Share - Vimarsana News

Brokerages Expect Kodiak Sciences Inc. (NASDAQ:KOD) Will Announce Earnings of -$1.47 Per Share

Analysts expect Kodiak Sciences Inc. (NASDAQ:KOD – Get Rating) to post earnings per share of ($1.47) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Kodiak Sciences’ earnings. The highest EPS estimate is ($0.73) and the lowest is ($1.80). Kodiak Sciences reported earnings per share of ($0.98) during the […]

Roth Capital Cuts Kodiak Sciences (NASDAQ:KOD) Price Target to $75.00 - Vimarsana News

Roth Capital Cuts Kodiak Sciences (NASDAQ:KOD) Price Target to $75.00

Kodiak Sciences (NASDAQ:KOD – Get Rating) had its price target trimmed by Roth Capital from $149.00 to $75.00 in a research note published on Monday, The Fly reports. KOD has been the subject of several other research reports. Barclays cut their price target on Kodiak Sciences from $81.00 to $50.00 and set an underweight rating […]

Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration - Vimarsana News

Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration

PALO ALTO, Calif., Feb. 23, 2022 /PRNewswire/ -- Kodiak Sciences Inc. today announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b/3 clinical... | February 23, 2022

Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration - Vimarsana News

Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD) today announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b/3...